Parkinson's Disease in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
Summary
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033.
GlobalData estimates that drug sales for PD in 2023 were approximately $3.4 billion across the 7MM. With an estimated $2.1 billion in drug sales in 2023, the US dominated the PD market, contributing 63.3% of the sales in the 7MM. The high market share is primarily due to the large PD prevalent population coupled with the cost of drugs, which is significantly higher in the US compared to other countries in the 7MM. The 5EU market contributed $674.3 million in sales in 2023, accounting for 20.0% of the global market. Japan contributed sales of $560.4 million in 2023, representing 16.6% of the total global market. GlobalData anticipates that the PD market will grow to be worth approximately $7.9 billion by 2033, at a compound annual growth rate (CAGR) of 8.9%. The US is expected to maintain its position as the market leader in 2033.
Across the 68 markets, sales in the Parkinson's Disease market were $5.7billion in 2023, growing to $12.4 billion in 2033. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 59.5% and 63.5% of 68-market sales in 2023 and 2033, respectively.
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook